FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Fundamental Analysis & Valuation

NASDAQ:FBIOP • US34960Q2084

13.62 USD
-0.03 (-0.22%)
Last: Mar 10, 2026, 01:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FBIOP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, FBIOP scores 3 out of 10 in our fundamental rating. FBIOP was compared to 519 industry peers in the Biotechnology industry. FBIOP may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FBIOP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. FBIOP Profitability Analysis

1.1 Basic Checks

  • FBIOP had negative earnings in the past year.
  • FBIOP had a negative operating cash flow in the past year.
  • In the past 5 years FBIOP always reported negative net income.
  • FBIOP had a negative operating cash flow in each of the past 5 years.
FBIOP Yearly Net Income VS EBIT VS OCF VS FCFFBIOP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With an excellent Return On Assets value of -2.94%, FBIOP belongs to the best of the industry, outperforming 86.51% of the companies in the same industry.
  • FBIOP has a Return On Equity of -9.55%. This is amongst the best in the industry. FBIOP outperforms 87.48% of its industry peers.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIOP Yearly ROA, ROE, ROICFBIOP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

  • FBIOP's Gross Margin of 71.56% is amongst the best of the industry. FBIOP outperforms 81.70% of its industry peers.
  • FBIOP's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for FBIOP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIOP Yearly Profit, Operating, Gross MarginsFBIOP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FBIOP Health Analysis

2.1 Basic Checks

  • FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FBIOP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for FBIOP has been increased compared to 5 years ago.
  • Compared to 1 year ago, FBIOP has a worse debt to assets ratio.
FBIOP Yearly Shares OutstandingFBIOP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIOP Yearly Total Debt VS Total AssetsFBIOP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • FBIOP has an Altman-Z score of -4.53. This is a bad value and indicates that FBIOP is not financially healthy and even has some risk of bankruptcy.
  • FBIOP has a Altman-Z score of -4.53. This is in the lower half of the industry: FBIOP underperforms 61.46% of its industry peers.
  • A Debt/Equity ratio of 0.86 indicates that FBIOP is somewhat dependend on debt financing.
  • FBIOP has a worse Debt to Equity ratio (0.86) than 72.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -4.53
ROIC/WACCN/A
WACC9.21%
FBIOP Yearly LT Debt VS Equity VS FCFFBIOP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

  • FBIOP has a Current Ratio of 2.19. This indicates that FBIOP is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.19, FBIOP is not doing good in the industry: 74.76% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.97 indicates that FBIOP should not have too much problems paying its short term obligations.
  • The Quick ratio of FBIOP (1.97) is worse than 75.53% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIOP Yearly Current Assets VS Current LiabilitesFBIOP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. FBIOP Growth Analysis

3.1 Past

  • FBIOP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.37%, which is quite impressive.
  • FBIOP shows a decrease in Revenue. In the last year, the revenue decreased by -0.32%.
  • The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%

3.2 Future

  • FBIOP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.19% yearly.
  • The Revenue is expected to grow by 64.44% on average over the next years. This is a very strong growth
EPS Next Y109.83%
EPS Next 2Y41.53%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FBIOP Yearly Revenue VS EstimatesFBIOP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIOP Yearly EPS VS EstimatesFBIOP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

2

4. FBIOP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FBIOP. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 1335.29, which means the current valuation is very expensive for FBIOP.
  • Based on the Price/Forward Earnings ratio, FBIOP is valued cheaper than 87.67% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.65, FBIOP is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 1335.29
FBIOP Price Earnings VS Forward Price EarningsFBIOP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600 800 1K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIOP Per share dataFBIOP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates FBIOP does not grow enough to justify the current Price/Earnings ratio.
  • FBIOP's earnings are expected to grow with 35.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.53%
EPS Next 3Y35.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FBIOP Dividend Analysis

5.1 Amount

  • FBIOP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FBIOP Fundamentals: All Metrics, Ratios and Statistics

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (3/10/2026, 1:39:31 PM)

13.62

-0.03 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-24
Inst Owners18.92%
Inst Owner ChangeN/A
Ins Owners14.74%
Ins Owner ChangeN/A
Market Cap422.76M
Revenue(TTM)62.30M
Net Income(TTM)-5.34M
Analysts82.5
Price Target42.99 (215.64%)
Short Float %0%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)1.39%
PT rev (3m)50.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)131.88%
EPS NY rev (1m)0%
EPS NY rev (3m)150%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1335.29
P/S 6.79
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 15.55
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)0.01
Fwd EY0.07%
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.01
BVpS1.8
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -4.53
F-Score4
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y109.83%
EPS Next 2Y41.53%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.86%
EBIT Next 3Y23.67%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ

Can you provide the ChartMill fundamental rating for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?

ChartMill assigns a fundamental rating of 3 / 10 to FBIOP.


What is the valuation status for FBIOP stock?

ChartMill assigns a valuation rating of 2 / 10 to FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP). This can be considered as Overvalued.


What is the profitability of FBIOP stock?

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a profitability rating of 2 / 10.


What is the earnings growth outlook for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?

The Earnings per Share (EPS) of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is expected to grow by 109.83% in the next year.